Clinical Trial Update: Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu [Phase 2]

View source ↗

Summary

Phase 2 clinical trial on Fuzheng Huayu for pulmonary fibrosis due to COVID-19 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis Due to COVID-19

Drugs mentioned

• Fuzheng Huayu

Snippet

Sponsor: ShuGuang Hospital | Conditions: Pulmonary Fibrosis Due to COVID-19 | Phase 2 | Status: COMPLETED